Search

Sandoz Group AG

Avatud

35.8 -4.15

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.68

Max

37.35

Põhinäitajad

By Trading Economics

Sissetulek

150M

Müük

5.1B

Dividenditootlus

1.62

Kasumimarginaal

2.963

Töötajad

22,049

EBITDA

541M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+17.51% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.62%

2.39%

Järgmine tulemuste avaldamine

30. apr 2025

Turustatistika

By TradingEconomics

Turukapital

16B

Eelmine avamishind

39.95

Eelmine sulgemishind

35.8

Sandoz Group AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. dets 2024, 07:45 UTC

Market Talk

Sandoz's U.S. Settlement to Cost 1.1 Swiss Francs a Share -- Market Talk

17. dets 2024, 07:34 UTC

Market Talk

Sandoz's U.S. Settlement Shows Commitment Move Forward -- Market Talk

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Sandoz Group AG Prognoos

Hinnasiht

By TipRanks

17.51% tõus

12 kuu keskmine prognoos

Keskmine 43.524 CHF  17.51%

Kõrge 50 CHF

Madal 38 CHF

Põhineb 8 Wall Streeti analüütiku instrumendi Sandoz Group AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

4

Osta

4

Hoia

0

Müü

Finantsandmed

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

$

Ettevõttest Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.